p53 gene transfer to the injured rat carotid artery decreases neointimal formation  by Scheinman, Marcel et al.
360
BASIC SCIENCE STUDIES
The process of neointimal formation that follows
invasive vascular procedures is very complex, involv-
ing a multitude of growth factors and signaling mol-
ecules. The effort to prevent this pathological
process has generated a wide range of studies involv-
ing pharmacological agents and gene therapy.1-5
These approaches have targeted a myriad of factors
found to be involved in the formation of neointima.
Some of the advantages of gene therapy over the
pharmacological approaches include the lack of sys-
temic toxicity and the more prolonged effect after a
single-dose treatment.1,6 Furthermore, the highest
inhibition of neointimal formation was obtained
with gene transfer experiments. Some of the genes
studied, like the nitric oxide synthase5 and basic
fibroblast growth factor3, have resulted in a 70% and
85% reduction in neointimal formation, respectively.
Nevertheless, the search for a gene that could com-
pletely arrest this process continues.
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· 109 pfu/mL. Control rats received either adenovirus null (AdNull), 8 · 1010 pfu/mL,
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vesting carotid arteries and determining the intima/media (I/M) ratio based on cross-
sectional area measurement. Simultaneously, immunohistochemistry was done to detect
the presence of p53 on smooth muscle cell nuclei.
Results: P53 expression was confirmed by Western blotting. There was a significant
reduction in neointimal formation on all treated animals compared with controls. The
highest dose of AdWTp53 (8 · 1010 pfu/mL) resulted in a near-total arrest of neointi-
mal formation (I/M = 0.09 ± 0.03, mean ± SEM) with P < .0001 versus vehicle (I/M
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the formation of neointima in the rat carotid injury model. This may represent a poten-
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Theoretically, better results could be achieved by
intervening directly in the cell cycle control. Targeting
the cell cycle can influence several growth factors and
signaling molecules at once. Genes known to be
involved in the cell cycle, like p21, a cyclin/cyclin-
dependent kinase inhibitor, and the retinoblastoma
gene (Rb), have been tested. The reduction in neoin-
timal formation obtained, however, was only ~50%, as
measured by the intima-to-media (I/M) ratio.6-8
The kinetics of expression of the cell cycle regu-
latory factors in response to vascular injury remain
largely unknown.9 Among the factors already dis-
covered, probably the one that has recently attract-
ed the most interest from the scientific community is
the p53 protein, mainly due to its key role on the
regulation of several types of cancers.
The p53 gene is located in 20 kb of the short
arm of chromosome 17 in the human genome. The
protein is composed of 393 amino acids and is a
nuclear phosphoprotein.10 The cells with wild-type
p53 protein react to DNA damage by blocking pro-
gression through the cell cycle and arresting in G1,
whereas DNA repair takes place before entry into S
phase.11-14 If repair does not occur, p53 induces
apoptosis.12-16 Cycle arrest in G1 is mediated by
induction of p21 (also known as WAF1/Cip1),
which binds to cyclin-dependent kinases inhibiting
their function, which in turn decreases the level of
phosphorylation of the retinoblastoma (Rb) pro-
tein.11-14,17,18 The Rb protein in its unphosphory-
lated state inactivates cellular transcription factors
that are required for cell cycle progression.6 It has
been demonstrated that p53 can induce apoptosis
and cell cycle arrest through independent mecha-
nisms12-14,19 other than p21 induction.
Given the multiple ways by which p53 controls
the cell cycle, its clinical application may represent a
powerful tool to prevent or decrease the formation of
neointima that follows vessel injury perhaps even
more so than p21 and Rb genes. The arrest of vascu-
lar smooth muscle cell growth mediated by p53 has
been demonstrated in vitro12,20,21 and, more recent-
ly, in vivo by Yonemitsu et al.22 Using the hemag-
glutinating virus of Japan with liposome as a vector
in the rabbit injured carotid artery, Yonemitsu et al
demonstrated a >80% reduction in the I/M of ani-
mals that received p53 gene compared with controls.
Besides the type of gene to be transferred, the
choice of vector also is a key element to achieve
good results. There are many vector that could be
used to transfer genes into the target cell; among
them, recombinant adenoviruses are very effi-
cient17,18,22,23 because they provide a high degree of
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infection and stable transgene expression. However,
duration is still limited by the immunogenicity that
triggers a host immune response. Because of their
capacity to infect slowly dividing cells, adenoviruses
are the preferred vectors to target vascular walls.
In the present experiment, we decided to study
the effect of p53 gene transfer in a different animal
model, the rat, and to use adenovirus as a vector.
This should help to expand the knowledge on the
effect of p53 gene in the injured vascular wall and to
confirm the results previously shown that places p53
as one of the most potent inhibitors of neointimal
formation.
MATERIAL AND METHODS
Adenoviral vectors. The construction of aden-
ovirus-expressing human wild-type p53 cDNA
(AdWTp53) and adenovirus null (AdNull) used as
control has been previously described in detail.12,13,25
Briefly, AdWTp53 was constructed using cotransfec-
tion of shuttle vector pDK10 containing the wild-type
p53 expression cassette and a plasmid pJM17 con-
taining the adenovirus type 5 genome, generating a
replicant-defective adenovirus through replacement
of the E1 region by the p53 cDNA cassette. AdNull
has a similar structure except that it is devoid of p53
expression cassette.
Viral culture and titration. AdWTp53 and
AdNull were propagated in human embryonic kid-
ney 293 cells (American Type Culture Collection,
Rockville, Md) grown in monolayers, suspended in
PBS (GIBCO BRL, Gaithersburg, Md), and stored
at –70°C. Titration was done using plaque-forming
assay. Briefly, 293 cells were cultured in 6-well tissue
culture plates (Falcon, Franklin Lakes, NJ) until
~70% to 80% confluent. Cells were infected with ser-
ial dilutions of virus (AdWTp53 and AdNull) and
incubated with soft agar media in a humidified envi-
ronment at 37°C in 5% CO2 and observed periodi-
cally for the appearance of plaques. Titers were
determined by adding Neutral red (GIBCO BRL)
and counting the plaques at days 10 and 12. Titers
were ~8 · 1010 plaque-forming units (pfu)/mL.
Animals. Adult male Sprague-Dawley rats
(Taconic Farms, Germantown, NY) weighing 450 to
500 g were used (n = 42). All animals received humane
care and treatment in compliance with the “Principles
of Laboratory Animal Care” (National Society for
Medical Research) and the “Guide for the Care and
Use of Laboratory Animals” (National Institutes of
Health publication No. 85-23, revised 1985) and were
approved by the Institutional Animal Care and Use
Committee of Maimonides Medical Center, Brooklyn,
NY. Animals were acclimated before experiments for
‡ 72 hours. Rats were anesthetized with an intraperi-
toneal injection of pentobarbital sodium (Abbott
Laboratories, Abbott Park, IL) in doses of 75 mg/kg.
Anticoagulation was obtained before carotid arteries
clamping by intravenous injection of porcine heparin
(100 USP U/kg; Abbott Laboratories). After surgery,
rats were returned to their cages and allowed water
and food ad libitum. Rats were killed on postoperative
day 4 or 14 according to the experimental protocol.
In vivo gene transfer into carotid artery.
Animals were divided in 5 groups according to the
type of solution infused in the artery: Group 1 (con-
trol), Medium-199 (Biofluids, Rockville, Md) con-
taining 1 mg/mL rat serum albumin (Sigma
Chemical, St Louis, Mo) (vehicle); group 2 (con-
trol), AdNull 8 · 1010 pfu/mL; group 3, AdWTp53
8 · 1010 pfu/mL; group 4, AdWTp53 1.6 · 1010
pfu/mL; and group 5, AdWTp53 8 · 109 pfu/mL.
Each group contained 8 rats, except for the
AdWTp53 8 · 1010 group, which contained 10 rats.
Two rats from each group were used for Western
blot assessment of protein expression, whereas the
remaining 32 rats were used for morphometric
analysis. The control AdNull was used at the highest
titration to be comparable to AdWTp53 8 · 1010
pfu/mL and to ensure that any result obtained
would not be due to viral toxicity. Vehicle alone also
was used as control to facilitate tissue proliferation.
Adenoviral vector stocks were thawed, diluted in
vehicle, and maintained on wet ice until use.
Through a midline neck incision, the left carotid
artery was surgically exposed. After systemic
heparinization, an arteriotomy was performed in the
external carotid artery. Balloon catheter injury was
performed as described by Clowes et al26 using a 2F
Fogarty balloon catheter (Baxter Healthcare, Santa
Ana, Calif). After 3 passages of the balloon, a seg-
ment of common carotid artery ~1 cm in length was
isolated between vascular clamps. A 24-gauge plastic
catheter was introduced through the arteriotomy,
and the isolated vessel segment was flushed with nor-
mal saline solution before the introduction of either
vector or control solutions. A total of 50 to 100 m L
of solution was instilled under pressure to keep the
isolated carotid segment distended. Intraluminal
pressures were measured during instillation, with a
pressure transducer coupled to a Honeywell
M2103B monitor (Honeywell, Pleasantville, NY),
and ranged from 160 to 200 mm Hg (data not
shown). These pressures, however, may be overesti-
mated due to the small caliber of the vessels and lim-
itations of the transducer. The manual pressure
applied during instillation was the minimum neces-
sary to achieve vessel distention. Incubation time was
30 minutes, and the intraluminal pressure was kept
constant. The solution then was withdrawn, and the
artery was rinsed with normal saline. The external
carotid was ligated, the blood flow was restored to
the common and internal carotid arteries, and the
neck incision was closed. 
Assessment of p53 expression by Western blot-
ting. To determine recombinant gene expression, rats
were killed 4 days after surgery (2 from each group;
total of 10). Vessels were harvested, immediately
homogenized in ice-cold buffer (20 mmol/L Tris, 
pH 7.4, 50 mmol/L NaCl, 10% SDS, 1 mmol/L
EDTA, 1 mmol/L EGTA, 0.2 mmol/L PMSF, 
1 m g/mL pepsatin, 0.5 m g/mL leupeptin, 0.2
mmol/L Na3VO4, 5 mmol/L mercaptoethanol), 
and centrifuged for 80 minutes at 16,000 rpm. 
2-Mercaptoethanol was added to lysates, and samples
were boiled for 5 minutes. Samples were loaded onto a
15% polyacrylamide minigel (15 m L each sample) for
electrophoresis at 200 V for 30 minutes using BioRad
Modular Mini Electrophoresis System (Hercules,
Calif). Blots were transferred to nitrocellulose paper on
the same system using a 4°C transfer buffer (25
mmol/L Tris, 92 mmol/L glycine, 20% v/v methanol)
and a cooling unit for 1 hour at 100 V. For detection,
proteins were probed with a purified, biotinylated
mouse anti-p53 monoclonal antibody (Oncogene
Science, Uniondale, NY) and incubated with horserad-
ish peroxidase-conjugated streptavidin secondary anti-
body and with the ECL chemiluminescent detection
system substrate (Amersham International, Amersham,
Bucks, UK) according to the manufacturer’s direc-
tions. Visualization of bands was possible after expo-
sure to x-ray film for 5 minutes in a dark room. 
Fixation and removal of vessel segments. Rats
(total of 32) were killed 14 days after surgery, and the
carotid vessels were perfusion-fixed in situ as follows.
The descending aorta was clamped, and the aortic
arch was cannulated with a 19-gauge butterfly. The
vessels were perfused with normal saline until clear of
blood and infused with 2% paraformaldehyde (Fisher
Scientific, Pittsburgh, Pa). After 1 hour, carotid ves-
sels were harvested. Cross sections were taken from
the center of the injured area (3 from each vessel, 2
mm apart) and subjected to morphometric analysis.
Morphometric analysis. After immersion fixa-
tion, tissue was paraffin-embedded, sectioned (5
m m), and stained (hematoxylin-eosin) for light
microscopy. Photomicrographs were taken, and the
intimal and medial cross-sectional areas were mea-
sured with a digitizer tablet and the Sigma-Scan
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Toxicity analysis. Blood samples were sent for
chemistry, including liver and kidney function tests,
electrolytes, complete blood count, and coagulation
profile. Tissue samples from liver, kidney, and aorta
were harvested; fixed in 10% formalin; embedded in
paraffin; stained with hematoxylin-eosin; and exam-
ined under the microscope.
Statistical analysis. Analysis of variance with
Newman-Keuls multiple comparison post-tests were
used to detect differences between groups, followed
by two-tailed Student’s t test to calculate the differ-
ences. Values were considered significant when P <
.05. Analysis was done using the software Winks
4.21 (TexaSoft, Cedar Hill, Tex).
RESULTS
Expression of p53 protein by Western blot-
ting. At 4 days after p53 gene transfection, signifi-
cant levels of protein expression were detected by
Western blotting compared with controls (Fig 1).
The monoclonal antibody used specifically recog-
nizes and binds to the p53 protein (53 kDa) in all its
isoforms. On the control groups, no bands were
visualized after incubation with the antibody, chemi-
luminescence, and x-ray exposure. This can be
explained by the fact that normal tissue, injured or
not, expresses p53 in an amount insufficient to be
detected with this method.
Effects of AdWTp53 transfer in the rat
carotid artery injury model. There was a signifi-
cant inhibition of neointimal formation, as deter-
mined by the I/M ratio, in all treatment groups
compared with controls. Results are expressed as
mean ± SEM. In the control groups, the I/M ratio
was 2.23 ± 0.15 for the vehicle and 2.12 ± 0.12 for
the AdNull (concentration of 8 · 1010 pfu/mL).
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software package (Jandel, San Rafael, Calif). The
I/M was calculated; the I/M of an uninjured artery
was considered to be 0 because it is 1 cell layer thick.
An I/M of ‡ 1.0 implies that the intimal area is equal
to or greater than the area of the media.
Immunohistochemistry for P53 protein.
Formalin-fixed, paraffin-embedded tissue sections
from the same blocks used for morphometric analysis
(14 days after surgery) were stained for p53 detection
as described previously.27,28 Briefly, slides of 5- m m-
thick sections from paraffin-embedded tissue were
dry heated in an oven overnight, dewaxed in xylene,
rehydrated, and pretreated by boiling in 10 mmol/L
citric acid buffer at 95°C for 30 minutes. Slides were
incubated with murine monoclonal anti-human p53
protein antibody (DO-7; DAKO, Carpinteria, CA)
diluted 1:200 in 0.05 mol/L Tris buffer (pH 7.6) for
10 minutes at room temperature, followed by incu-
bation with secondary antibodies biotinylated link
(for 15 minutes) and streptavidin peroxidase (for 15
minutes) in room temperature. Immunostaining was
performed with diaminobenzidine chromogen
(DAKO) for 5 to 6 minutes as recommended in the
LSAB2 kit (DAKO). The sections were counter-
stained with Mayer’s hematoxylin.
Evaluation of immunostaining was done with an
Olympus BX40 microscope (Olympus Optical,
Tokyo, Japan) at · 400 magnification. Analysis was
done by an experienced pathologist (G.S.L.) who
was blinded to the type of treatment used. Staining
was subjectively quantified. When present in >30%
of smooth muscle cell nuclei in the media, it was
designated as positive; when present in 10% to 30%
of nuclei, it was designated as indeterminate; and
when present in <10%, it was negative.
Assessment of reendothelialization by immuno-
histochemistry for von Willebrand factor.
Formalin-fixed, paraffin-embedded tissue sections of
specimens from animals treated with AdWTp53
(groups 3 and 4, n = 5 from each group) were stained
for von Willebrand factor (vWF). Briefly, slides of 5-
m m-thick sections were dry heated in oven overnight,
dewaxed in xylene, rehydrated, and stained according
to the manufacturer’s instructions (N1505; DAKO).
Slides were incubated with primary antibody for 10
minutes, followed by incubation with secondary anti-
bodies biotinylated link (for 10 minutes) and strepta-
vidin peroxidase (for 10 minutes) in room tempera-
ture. Immunostaining was performed by incubation
with liquid diaminobenzidine chromogen (K3465;
DAKO) for 20 minutes. The sections were counter-
stained with hematoxylin and visualized under light
microscopy at · 400 magnification.
Fig 1. Western blot analysis of p53 expression in rat
carotid arteries 4 days after balloon injury. Positive detec-
tion is shown on lanes 1, 2, and 3 (AdWTp53, 8 · 109
pfu/mL, 1.6 · 1010 pfu/mL, and 8 · 1010 pfu/mL,
respectively), whereas lanes 4 (vehicle) and 5 (AdNull)
show an absence of p53 bands.
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The highest dose of AdWTp53, 8 · 1010 pfu/mL,
resulted in almost complete arrest of intimal thick-
ening, with an I/M ratio of 0.09 ± 0.03. This reduc-
tion of neointimal formation was statistically signifi-
cant (P < .0001) compared with controls. In 3 of 8
rats, only a single layer of endothelial cells was visu-
alized (I/M = 0). Also, in these 3 rats, we observed
a marked decrease in the number of smooth muscle
cell nuclei within the media. A significant reduction
of neointimal formation was observed in the
AdWTp53 intermediate (1.6 · 1010 pfu/mL) and
lowest (8 · 109 pfu/mL) viral concentration groups
compared with vehicle (P < .001) and AdNull (P <
.002), with an I/M ratio of 1.04 ± 0.18 and 1.12 ±
0.18, respectively. The reduction obtained with the
highest concentration of AdWTp53 was significant
compared with the intermediate and lowest concen-
trations (P = .003 and .002, respectively). However,
no significant difference existed between the 2 low-
est concentrations (P = .79). These results are illus-
trated in Fig 2, and photomicrographic examples are
shown in Fig 3.
Immunohistochemistry for p53. An explana-
tion is necessary regarding the criteria of staining
evaluation. Initially, we intended to differentiate only
between positive and negative staining. However,
due to a heavy background staining in some of the
control specimens, we arbitrarily chose to consider
positive only those sections with ‡ 30% of smooth
muscle cell nuclear staining. From the 96 sections
analyzed (3 sections from each of the 32 speci-
mens), a reasonable separation between positive and
negative staining was obtained in 84% (27 of 32
specimens). Staining of smooth muscle cell nuclei
was observed within the media, whereas the nuclei
of cells within the intimal proliferation did not
stain. In the AdWTp53 groups, 65% of the rats (7
of 20) had positive results, with nuclear staining
varying between 30% to 50%. Three rats of the
highest-dose p53 gene transfer exhibited negative
results. In these 3 specimens, complete arrest of
neointimal formation occurred and no staining
could be appreciated. This could be due to a
marked decrease in the smooth muscle cell nuclei
number that was clearly observed in these sections.
Results are illustrated in Fig 4.
Immunohistochemistry for von Willebrand
factor. Positive staining in the luminal cellular layer
was observed in all 10 specimens studied. Results are
illustrated in Fig 5.
Toxicity of AdWTp53. No pathological
changes were found at light microscopy analysis of
tissue samples from animals treated with AdWTp53.
Also, blood count, coagulation profile, electrolytes,
renal function, and liver function tests showed no
statistically significant changes on rats transfected
with AdWTp53 compared with controls. Table I
shows the main blood chemistry values.
Fig 2. Inhibition of neointima formation by AdWTp53 gene transfer 14 days after balloon
injury of the rat carotid artery. The data are shown as mean ± SEM. The AdWTp53 groups
have 3 concentrations: #1, 8 · 1010 pfu/mL; #2, 1.6 · 1010 pfu/mL; and #3, 8 · 109 pfu/mL.
Group 1 has 8 animals, whereas the remaining groups have 6 animals in each. *P < .001 ver-
sus controls (vehicle + AdNull, 8 · 1010 pfu/mL). **P = .003 versus AdWTp53 #1. ***P =
.002 versus AdWTp53 #1 by Student’s t test.
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DISCUSSION
We hypothesized that p53 would be a powerful
tool to decrease neointimal formation because it has a
multifactorial role in controlling the cell cycle. In this
study, a statistically significant reduction occurred in
all treated groups transfected with AdWTp53 com-
pared with controls. With the highest viral titration
group, we observed a complete inhibition of neointi-
mal formation in 3 of 8 cases and a >90% reduction in
the remaining 5 cases. These effects could not be
Fig 3. Inhibition of neointima formation by
AdWTp53. Representative photomicrographs
of cross sections from rat carotid arteries 14
days after surgery. Cross sections were taken
from the center of each vessel. The neointima
is demarcated between arrows. (A) AdNull.
(B) AdWTp53, 8 · 1010 pfu/mL; near-total
arrest of neointimal formation. (C) Vehicle.
(D) AdWTp53, 1.6 · 1010 pfu/mL. (E)
AdWTp53, 8 · 1010 pfu/mL; 1 layer of cells
is shown. The photomicrographs illustrate the
effect of AdWTp53 on decreasing neointima
formation. Hematoxylin-eosin. Magnification:
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attributed to the toxicity of the high adenovirus titer
because a similar titer of AdNull resulted in neointi-
mal formation at a magnitude comparable to the vehi-
cle group. Moreover, we obtained an inhibition of
neointimal formation at least as good as that obtained
by Yonemitsu et al22 using a different animal species
and a different vector.
The exact mechanism by which p53 acted is
Fig 4. Immunohistochemistry for p53. (a) Negative staining. (b) Positive staining. A =
adventitia; M = media; NI = neointima; I = intima. Arrow shows stained nucleus. Mayer’s
hematoxylin, magnification · 400.
Table I. Systemic Toxicity Analysis: Blood Chemistry
Group WBC Hematocrit Cr Glu Ca2+ AST PT
Vehicle 7.7 ± 1 36 ± 5 40 ± 7 119 ± 15 10 ± 0.9 101 ± 10 1.1 ± 0.7
AdNull 7.0 ± 0.9 41 ± 6 36 ± 4 130 ± 18 11 ± 1 90 ± 7 1.2 ± 0.9
p53 #1* 6.9 ± 0.8 37 ± 3 42 ± 5 126 ± 11 9 ± 1 89 ± 8 1.0 ± 0.6
p53 #2† 7.7 ± 1.1 42 ± 7 40 ± 6 121 ± 12 10 ± 1 103 ± 11 0.9 ± 0.6
p53 #3‡ 5.9 ± 0.6 33 ± 4 41 ± 4 118 ± 11 11 ± 0.9 100 ± 9 1.3 ± 1
*AdWTp53 8 · 1010 pfu/mL.
†AdWTp53 1.6 · 1010 pfu/mL.
‡AdWTp53 8 · 109 pfu/mL.
Values for WBC are 103/m L; values for hematocrit are percent; values for Cr (creatinine), Glu (glucose), and Ca2+ (calcium) are mg/dL;
values for AST (aspartate aminotransferase) are IU/L; values for PT (prothrombin time) are times compared with control.
All values are expressed as mean ± SEM.
A
B
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unclear. However, one can speculate based on previ-
ous studies that upregulation of p21 and Rb genes
may be a key mechanism in this process. It has been
demonstrated that wild-type p53 transcriptionally
activates p21 expression by directly interacting with
its regulatory elements. The p21 gene binds to cel-
lular cyclin-dependent kinases inhibiting their func-
tion, which in turn decreases the level of phospho-
rylation of the Rb protein,11,13 resulting in arrest of
the cell cycle. Previous studies using p21 and Rb
genes in the rat carotid artery injury model17,18
demonstrated an ~50% reduction in neointimal for-
mation. However, a 96% reduction in neointimal
formation achieved with p53 suggests that other
mechanisms, such as apoptosis, may play a role.
Tumor suppressor genes such as p53 have been
shown to be potent regulators of apoptosis.13,18,19
The mechanism by which p53 induces apoptosis has
not been yet elucidated; however, the relationship
between the development of several types of cancers
and the presence of mutant p53 has been well estab-
lished. Wild-type p53 is able to induce apoptosis,
Fig 5. Immunohistochemistry for von Willebrand factor. Positive staining (arrows) observed
in the endothelium of rat carotid arteries after balloon injury and p53 gene transfer. (A)




whereas mutant p53 lacks this capacity. In the pre-
sent study, we did not perform any assay to detect
apoptosis. In a subsequent experiment, however, we
observed that apoptosis was present after p53 gene
transfer to the injured rat carotid artery. Treated ani-
mals received AdWTp53 8 · 1010 pfu/mL, whereas
control animals received AdNull at the same titra-
tion. Arteries were harvested at 24 and 48 hours
after the procedure. Apoptosis was detected in tissue
sections by in situ terminal deoxynucleotidyl trans-
ferase-mediated dUTP nick end labeling (TUNEL)
assay, DNA agarose gel electrophoresis, and trans-
mission electron microscopy. With the TUNEL
assay, no apoptosis was visualized at 24 and 48 hours
in the controls (n = 5 in each group), whereas in the
AdWTp53 groups (n = 5 in each), all specimens pre-
sented apoptosis (P < .05, AdWTp53 versus con-
trols). Electron microscopy also confirmed the find-
ings of apoptosis (unpublished data).
Another question that remains unanswered is if
p53-mediated apoptosis plays a role, would cytotoxi-
city be a major side effect? One study had shown
AdWTp53 mediated cytotoxicity to vascular smooth
muscle cells in vitro12 by arrest of cell culture growth.
In contrast, the same group reported that in vitro cul-
ture of normal epithelial cells showed resistance to
apoptosis with continued growth after AdWTp53
transfection.13 No evidence exists suggesting p53-
mediated cytotoxicity in vivo. Furthermore, several
studies on cancer have demonstrated that p53 plays
little role in normal cell cycle and has an important
growth-controlling role only in stressed cells.29 The
positive staining for vWF observed in the p53-treated
animals suggests that reendothelialization occurred;
however, this method alone and at one time point
only does not allow a final conclusion to be made.
Therefore, even though this observation points
against direct cytotoxicity, more evidence is needed to
prove it. No systemic toxicity was found with the use
of AdWTp53.
The immunohistochemistry failed to detect p53 in
one third of the cases of AdWTp53 transfer. The rea-
son could be the short half-life of the wild-type p53
(5 to 20 minutes)10,15,30 or that the amount of p53
protein was too low to be detected by immunohisto-
chemistry at 14 days after transfection. We chose to
use immunohistochemistry at 14 days and not earlier
for 2 reasons: (1) because protein expression was
already shown at 4 days by Western blotting, we were
interested to study whether p53 was being expressed
at a longer period, and (2) by using this method,
paraffin blocks from the same specimens used for
morphometric analysis could be used. Nevertheless,
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the protein production obtained at 14 days, as
demonstrated by the immunohistochemistry, is signif-
icantly high and suggests prolonged transgene expres-
sion. Considering that many cells may be undergoing
apoptosis, a possible explanation for this high protein
expression would be that many cells within the media
remained intact but were transferred with p53 gene.
We do not know the exact reason why 3 of the
specimens from the highest p53 titration group pre-
sented a marked reduction in the smooth muscle cell
nuclei within the media. We can speculate that per-
haps these cells underwent apoptosis induced by wild-
type p53 gene, whereas in the controls or in the lower
AdWTp53 titration, no or less apoptosis may have
occurred, and therefore the damaged cells proliferat-
ed to create the neointima. This reduction in medial
smooth muscle cells can be appreciated on Fig 3B.
The strongest neointima formation inhibition
achieved with the highest AdWTp53 titer is consis-
tent with previous studies in which adenoviral vec-
tors at similar titrations were used3,23 and can be
explained by the fact that adenovirus does not inte-
grate with the host genome, thus requiring high
titers to produce effect.
The most important limitation of adenoviral vec-
tors for gene therapy is the duration of gene expres-
sion, which is limited by the host immune response
against the virus. Therefore, it would be interesting
to know the duration of p53 expression after aden-
ovirus-mediated gene transfer in terms of determin-
ing its efficacy as potential treatment for neointimal
formation. We are starting a study to determine a
time-response curve.
In conclusion, adenovirus-mediated p53 gene
transfer is an efficient way to decrease neointimal
formation in the rat carotid injury model. Because
this is not an ideal model of human restenosis, future
experiments should be carried in larger animal mod-
els before considering the p53 gene as a potential
therapy for restenosis in humans. Further studies are
also required to fully elucidate the mechanism of
action of p53 and to better define the role of p53-
induced apoptosis.
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